T. Rowe Price Associates
FENC icon

T. Rowe Price Associates’s Fennec Pharmaceuticals FENC Stock Holding History

T. Rowe Price Associates’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
23,029
+6,164
+37% +$50.3K ﹤0.01% 2928
2026
Q1 		$104K Buy
16,865
+4,361
+35% +$33.7K ﹤0.01% 2993
2025
Q4 		$97K Hold
12,504
– – ﹤0.01% 2950
2025
Q3 		$118K Buy
12,504
+1,284
+11% +$11.1K ﹤0.01% 2896
2025
Q2 		$94K Buy
+11,220
New +$76.8K ﹤0.01% 2906

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

T. Rowe Price Associates's FENC Position: Q2 2026 in Review

T. Rowe Price Associates increased its Fennec Pharmaceuticals (FENC) stake by 37% in Q2 2026, buying an estimated $50.3K and bringing the position to 23,029 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

T. Rowe Price Associates first reported a position in FENC in Q2 2025 and has held it in 5 quarters since. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • T. Rowe Price Associates held 23,029 shares of Fennec Pharmaceuticals worth $248K as of Q2 2026.
  • T. Rowe Price Associates bought 6,164 Fennec Pharmaceuticals shares in Q2 2026, an estimated $50.3K.
  • Fennec Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2928 holding.
  • T. Rowe Price Associates first reported a position in Fennec Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.